Matching articles for "Detrol"

Drugs for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • March 20, 2023;  (Issue 1672)
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with...
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5 | Show Full IntroductionHide Full Introduction

Drugs for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • May 2, 2022;  (Issue 1649)
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to...
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Med Lett Drugs Ther. 2022 May 2;64(1649):65-9 | Show Full IntroductionHide Full Introduction

Vibegron (Gemtesa) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • May 3, 2021;  (Issue 1623)
The FDA has approved the selective beta-3 adrenergic agonist vibegron (Gemtesa – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency,...
The FDA has approved the selective beta-3 adrenergic agonist vibegron (Gemtesa – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is the second beta-3 agonist to be approved in the US; mirabegron (Myrbetriq) was the first.
Med Lett Drugs Ther. 2021 May 3;63(1623):67-9 | Show Full IntroductionHide Full Introduction

In Brief: Oxytrol OTC

   
The Medical Letter on Drugs and Therapeutics • September 16, 2013;  (Issue 1425)
The transdermal patch formulation of the anticholinergic drug oxybutynin (Oxytrol – Watson) is now available over the counter (OTC) as Oxytrol for Women (MSD) for use in women with overactive bladder (OAB)....
The transdermal patch formulation of the anticholinergic drug oxybutynin (Oxytrol – Watson) is now available over the counter (OTC) as Oxytrol for Women (MSD) for use in women with overactive bladder (OAB). It is the first treatment for OAB to become available OTC. Oxybutynin remains available only by prescription for men.

OAB, characterized by symptoms of urgency, frequency, and incontinence with no obvious cause, occurs mainly in older women.1 Behavioral modification, including fluid schedules, timed voiding, pelvic exercises, and urge suppression, is usually tried first.

Anticholinergic drugs such as oxybutynin and tolterodine (Detrol, and others) reduce OAB symptoms by relaxing bladder smooth muscle and inhibiting involuntary detrusor contractions. Dry mouth has been the limiting adverse effect. In clinical studies, the oxybutynin patch was associated with fewer systemic adverse effects, including dry mouth, than the oral drug, but with a high incidence of pruritus at the application site.2

Oxytrol and Oxytrol for Women both deliver 3.9 mg of oxybutynin per 24 hours and are applied every 4 days, but a box of 8 prescription Oxytrol patches costs $320.32,3 while an 8-patch box of OTC Oxytrol for Women costs only $29.99.4

1. EA Gormley et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188:2455.

2. Oxybutynin transdermal (Oxytrol) for overactive bladder. Med Lett Drugs Ther 2003; 45:38.

3. Wholesale acquisition cost (WAC). Source: $ource® Monthly (Selected from FDB MedKnowledge™) September 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail price may be higher.

4. Cost according to drugstore.com. Accessed September 5, 2013.

Download complete U.S. English article

Med Lett Drugs Ther. 2013 Sep 16;55(1425):76 | Show Full IntroductionHide Full Introduction

Botox for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • April 15, 2013;  (Issue 1414)
The FDA has recently approved intradetrusor injection of onabotulinumtoxinA (Botox – Allergan) for treatment of overactive bladder in patients who cannot tolerate or have an inadequate response to...
The FDA has recently approved intradetrusor injection of onabotulinumtoxinA (Botox – Allergan) for treatment of overactive bladder in patients who cannot tolerate or have an inadequate response to anticholinergic therapy. Botox is also approved by the FDA for use in detrusor overactivity associated with a neurologic condition such as multiple sclerosis or spinal cord injury, and for chronic migraine, upper limb spasticity, axillary hyperhidrosis, cervical dystonia, blepharospasm, strabismus, and cosmetic reduction of wrinkles.
Med Lett Drugs Ther. 2013 Apr 15;55(1414):31-2 | Show Full IntroductionHide Full Introduction

Mirabegron (Myrbetriq) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • February 18, 2013;  (Issue 1410)
Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic...
Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic agonist to be approved for any indication in the US. Mirabegron has been marketed in Japan since 2011. OnabotulinumtoxinA (Botox) was also recently approved by the FDA for treatment of overactive bladder and will be reviewed in a future issue.
Med Lett Drugs Ther. 2013 Feb 18;55(1410):13-5 | Show Full IntroductionHide Full Introduction

Fesoterodine (Toviaz) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • May 4, 2009;  (Issue 1311)
The FDA has approved the marketing of fesoterodine (Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this...
The FDA has approved the marketing of fesoterodine (Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.
Med Lett Drugs Ther. 2009 May 4;51(1311):34-5 | Show Full IntroductionHide Full Introduction

CYP3A and Drug Interactions

   
The Medical Letter on Drugs and Therapeutics • July 4, 2005;  (Issue 1212)
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the...
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.
Med Lett Drugs Ther. 2005 Jul 4;47(1212):54-5 | Show Full IntroductionHide Full Introduction

Solifenacin and Darifenacin for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • March 14, 2005;  (Issue 1204)
Solifenacin succinate (VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide (Enablex - Novartis) have been approved by the FDA for oral treatment of overactive...
Solifenacin succinate (VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide (Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.
Med Lett Drugs Ther. 2005 Mar 14;47(1204):23-4 | Show Full IntroductionHide Full Introduction

Trospium (Sanctura): Another Anticholinergic for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • August 2, 2004;  (Issue 1188)
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available...
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
Med Lett Drugs Ther. 2004 Aug 2;46(1188):63-4 | Show Full IntroductionHide Full Introduction

Oxybutynin Transdermal (Oxytrol) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • May 12, 2003;  (Issue 1156)
A patch formulation of oxybutynin (Oxytrol - Watson) is now available for treatment of overactive bladder. It is claimed to be as effective as the oral drug, with less dry...
A patch formulation of oxybutynin (Oxytrol - Watson) is now available for treatment of overactive bladder. It is claimed to be as effective as the oral drug, with less dry mouth.
Med Lett Drugs Ther. 2003 May 12;45(1156):38-9 | Show Full IntroductionHide Full Introduction

Tolterodine--A New Drug for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • October 23, 1998;  (Issue 1038)
Tolterodine tartrate (Detrol - Pharmacia & Upjohn) is a new muscarinic receptor antagonist now being widely promoted for treatment of urinary frequency, urgency and urge incontinence caused by bladder...
Tolterodine tartrate (Detrol - Pharmacia & Upjohn) is a new muscarinic receptor antagonist now being widely promoted for treatment of urinary frequency, urgency and urge incontinence caused by bladder (detrusor) overactivity.
Med Lett Drugs Ther. 1998 Oct 23;40(1038):101-2 | Show Full IntroductionHide Full Introduction